Early [18F]florbetaben and [11C]PiB PET images are a surrogate biomarker of neuronal injury in Alzheimer’s disease
暂无分享,去创建一个
Matthias L. Schroeter | Swen Hesse | Marianne Patt | Osama Sabri | Solveig Tiepolt | Julia Luthardt | Henryk Barthel | Karl-Titus Hoffmann | Hermann-Josef Gertz | David Weise | M. Schroeter | K. Hoffmann | D. Weise | H. Gertz | S. Tiepolt | J. Luthardt | M. Patt | S. Hesse | O. Sabri | H. Barthel
[1] Peter Herscovitch,et al. Appropriate use criteria for amyloid PET: A report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association , 2013, Alzheimer's & Dementia.
[2] Masanori Ichise,et al. PET Quantification of 18F-Florbetaben Binding to β-Amyloid Deposits in Human Brains , 2013, The Journal of Nuclear Medicine.
[3] Gunnar Antoni,et al. Unidirectional Influx and Net Accumulation of PIB , 2008, The open neuroimaging journal.
[4] M. Hüll,et al. Dual-Biomarker Imaging of Regional Cerebral Amyloid Load and Neuronal Activity in Dementia with PET and 11C-Labeled Pittsburgh Compound B , 2011, The Journal of Nuclear Medicine.
[5] H. Gertz,et al. Individualized quantification of brain β-amyloid burden: results of a proof of mechanism phase 0 florbetaben PET trial in patients with Alzheimer’s disease and healthy controls , 2011, European Journal of Nuclear Medicine and Molecular Imaging.
[6] Eveliina Arponen,et al. Visual assessment of [11C]PIB PET in patients with cognitive impairment , 2010, European Journal of Nuclear Medicine and Molecular Imaging.
[7] J. Morris,et al. The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.
[8] Nick C Fox,et al. Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria , 2014, The Lancet Neurology.
[9] Arno Villringer,et al. Differential effects of global and cerebellar normalization on detection and differentiation of dementia in FDG-PET studies , 2010, NeuroImage.
[10] M. Folstein,et al. Clinical diagnosis of Alzheimer's disease , 1984, Neurology.
[11] C. Rowe,et al. Comparison of 11C-PiB and 18F-florbetaben for Aβ imaging in ageing and Alzheimer’s disease , 2012, European Journal of Nuclear Medicine and Molecular Imaging.
[12] Anton Forsberg,et al. The use of PIB-PET as a dual pathological and functional biomarker in AD. , 2012, Biochimica et biophysica acta.
[13] A. Drzezga,et al. Current status and future role of brain PET/MRI in clinical and research settings , 2015, European Journal of Nuclear Medicine and Molecular Imaging.
[14] Matthias L. Schroeter,et al. Combined Imaging Markers Dissociate Alzheimer's Disease and Frontotemporal Lobar Degeneration – An ALE Meta-Analysis , 2011, Front. Ag. Neurosci..
[15] John Seibyl,et al. Cerebral amyloid-β PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study , 2011, The Lancet Neurology.
[16] J. Seibyl,et al. The role of positron emission tomography imaging in understanding Alzheimer’s disease , 2015, Expert review of neurotherapeutics.
[17] I. Apostolova,et al. Association between FDG uptake, CSF biomarkers and cognitive performance in patients with probable Alzheimer's disease , 2009 .
[18] John Seibyl,et al. Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease: Phase 3 study , 2015, Alzheimer's & Dementia.
[19] C. Jack,et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade , 2010, The Lancet Neurology.
[20] S. Pappatà,et al. Appropriate use criteria for amyloid PET imaging cannot replace guidelines: On behalf of the European Association of Nuclear Medicine , 2013, European Journal of Nuclear Medicine and Molecular Imaging.
[21] P. Scheltens,et al. Atrophy of medial temporal lobes on MRI in "probable" Alzheimer's disease and normal ageing: diagnostic value and neuropsychological correlates. , 1992, Journal of neurology, neurosurgery, and psychiatry.
[22] S. DeKosky,et al. Kinetic Modeling of Amyloid Binding in Humans using PET Imaging and Pittsburgh Compound-B , 2005, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[23] D. Yves von Cramon,et al. Neural networks in frontotemporal dementia—A meta-analysis , 2008, Neurobiology of Aging.
[24] T. Yen,et al. Correlation of early-phase 18F-florbetapir (AV-45/Amyvid) PET images to FDG images: preliminary studies , 2012, European Journal of Nuclear Medicine and Molecular Imaging.
[25] H. Engler,et al. Dynamic changes in PET amyloid and FDG imaging at different stages of Alzheimer's disease , 2012, Neurobiology of Aging.
[26] Cindee M. Madison,et al. Early 11C-PIB Frames and 18F-FDG PET Measures Are Comparable: A Study Validated in a Cohort of AD and FTLD Patients , 2011, The Journal of Nuclear Medicine.
[27] Swen Hesse,et al. Influence of scan duration on the accuracy of β-amyloid PET with florbetaben in patients with Alzheimer’s disease and healthy volunteers , 2012, European Journal of Nuclear Medicine and Molecular Imaging.
[28] Matthias L. Schroeter,et al. Neural correlates of Alzheimer's disease and mild cognitive impairment: A systematic and quantitative meta-analysis involving 1351 patients , 2009, NeuroImage.